Literature DB >> 1345813

Leukoregulin and gamma-interferon inhibit human papillomavirus type 16 gene transcription in human papillomavirus-immortalized human cervical cells.

C D Woodworth1, U Lichti, S Simpson, C H Evans, J A DiPaolo.   

Abstract

The human papillomavirus (HPV) transforming genes E6 and E7 are retained and expressed in the majority of cervical cancers implying an important role for these proteins in maintenance of the malignant phenotype. Leukoregulin (LR) and recombinant gamma-interferon (r-IFN-gamma), lymphokines secreted by immune cells present in regressing HPV infections, inhibited transcription of E6/E7 RNAs in several human cervical epithelial cell lines immortalized by recombinant HPV-16, -18, and -33 DNAs. r-IFN alpha was not effective. Reduction in E6/E7 RNA expression was accompanied by inhibition of cell proliferation coincident with an increase in epidermal transglutaminase activity, a marker of squamous differentiation. LR and r-IFN gamma enhanced transcription of class 1 cell surface histocompatibility antigens (HLA) and r-IFN gamma additionally induced HLA class 2 expression. HPV-immortalized cells developed partial resistance to the growth inhibitory effects of lymphokines after malignant transformation or extended propagation in culture. This is the first demonstration that LR and r-IFN gamma selectively inhibit transcription of HPV-transforming genes and suggests a molecular mechanism by which these lymphokines participate in regression of premalignant cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1345813

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

Review 1.  Cell-mediated immune response to human papillomavirus infection.

Authors:  M Scott; M Nakagawa; A B Moscicki
Journal:  Clin Diagn Lab Immunol       Date:  2001-03

2.  Differential expression of the monocyte chemoattractant protein-1 gene in human papillomavirus-16-infected squamous intraepithelial lesions and squamous cell carcinomas of the cervix uteri.

Authors:  L Riethdorf; S Riethdorf; K Gützlaff; F Prall; T Löning
Journal:  Am J Pathol       Date:  1996-11       Impact factor: 4.307

Review 3.  Human papillomaviruses and cervical neoplasia. II. Interaction of HPV with other factors.

Authors:  C S Herrington
Journal:  J Clin Pathol       Date:  1995-01       Impact factor: 3.411

Review 4.  Warts and all: human papillomavirus in primary immunodeficiencies.

Authors:  Jennifer W Leiding; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2012-10-01       Impact factor: 10.793

5.  NF-IL6 represses early gene expression of human papillomavirus type 16 through binding to the noncoding region.

Authors:  S Kyo; M Inoue; Y Nishio; K Nakanishi; S Akira; H Inoue; M Yutsudo; O Tanizawa; A Hakura
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

6.  Inhibition of growth, transformation, and expression of human papillomavirus type 16 E7 in human keratinocytes by alpha interferons.

Authors:  M A Khan; W H Tolleson; J D Gangemi; L Pirisi
Journal:  J Virol       Date:  1993-06       Impact factor: 5.103

7.  Cognitive behavioral stress management effects on psychosocial and physiological adaptation in women undergoing treatment for breast cancer.

Authors:  Michael H Antoni; Suzanne Lechner; Alain Diaz; Sara Vargas; Heather Holley; Kristin Phillips; Bonnie McGregor; Charles S Carver; Bonnie Blomberg
Journal:  Brain Behav Immun       Date:  2008-09-20       Impact factor: 7.217

8.  Differences of reactivity to interferon gamma in HeLa and CaSki cells: a combined immunocytochemical and flow-cytometric study.

Authors:  G Lizard; M C Chignol; Y Chardonnet; D Schmitt
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 9.  Molecular events in uterine cervical cancer.

Authors:  S A Southern; C S Herrington
Journal:  Sex Transm Infect       Date:  1998-04       Impact factor: 3.519

10.  Differential regulation of the JE gene encoding the monocyte chemoattractant protein (MCP-1) in cervical carcinoma cells and derived hybrids.

Authors:  F Rösl; M Lengert; J Albrecht; K Kleine; R Zawatzky; B Schraven; H zur Hausen
Journal:  J Virol       Date:  1994-04       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.